Hepatitis B Clinical Trial
Official title:
Real-life Data of Switching From Tenofovir Disoproxi Fumarate (TDF) to Tenofovir Alafenamide (TAF) in Virologically Suppressed Chronic Hepatitis B Patients With Antiviral Resistance
- To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus
continued tenofovir disoproxil fumarate (TDF) 300 mg QD in CHB patients with antiviral
resistance, as determined by the proportion of virologically suppressed patients at week
48
- To evaluate the safety and tolerability of switching to TAF 25 mg QD versus continuing
TDF 300 mg QD in antiviral-resistant subjects with chronic HBV at week 48
The investigators will conduct a multicenter observational study to evaluate the safety and
efficacy of TAF 25 mg QD in chronic hepatitis B patients with antiviral resistance who switch
from TDF to TAF. The safety and antiviral activity will be assessed as a part of routine
medical care. Subjects will be obtained from an existing cohort of patients treated with a
TDF-based regimen due to antiviral resistance, which has been supported by Gilead
(IN-US-174-1255).
It is anticipated that approximately 300 CHB patients with antiviral resistance taking TDF
300 mg QD will be enrolled in this study. All consecutive patients will be allocated to
receive either TAF 25 mg QD or TDF 300 mg QD (possibly 50% vs. 50%, the proportion of
patients enrolled in the study is an estimate based on the clinical experience.), according
to the decision of the individual patients and their physicians, with informed consent.
Patients are switched independently based on physicians discretion/decision prior to study
enrollment, and the study protocol would NOT have any influence over the process.
All consecutive patients will be prospectively monitored every 6 months during the first year
and thereafter every 6 months up to 3 years. At each visit, a routine examination and
determination of biochemical and virological parameters (HBV DNA level, HBeAg, anti-HBe,
HBsAg [quantitatively, if available], and anti-HBs) will be performed. Lab tests and markers
will be routinely monitored every 6 months.
Recruitment method: In this study, we plan to use an existing cohort of patients treated with
a TDF-based regimen due to antiviral resistance (IN-US-174-1255). Data on all consecutive
patients currently receiving TDF due to antiviral resistance at enrollment will be followed
up prospectively every 3-6 months for 2 years. The patients will be recruited consecutively.
Patients will be recruited only after the treatment decision has been made. No aspect of this
study will interfere with or influence routine medical practice.
Number of study sites: At least seven representative institutes in South Korea. Target
population: Korean adult subjects with CHB receiving TDF due to antiviral resistance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01182311 -
Duration of Long-term Immunity After Hepatitis B Virus Immunization
|
||
Completed |
NCT04971928 -
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
|
Phase 1 | |
Completed |
NCT03285620 -
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
|
Phase 1 | |
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05404919 -
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
|
Phase 2 | |
Completed |
NCT02153320 -
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Completed |
NCT03567382 -
Arresting Vertical Transmission of Hepatitis B Virus
|
Phase 4 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Not yet recruiting |
NCT03604016 -
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Completed |
NCT02540538 -
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
|
Phase 1 | |
Terminated |
NCT02604199 -
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Completed |
NCT02421666 -
A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV
|
N/A | |
Completed |
NCT02169674 -
Hepatitis B Booster Study in Adolescence
|
Phase 4 | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01732354 -
Study for Consolidation Period of Chronic Hepatitis B
|
||
Completed |
NCT01368497 -
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 3 | |
Recruiting |
NCT01462981 -
Cohort of Hepatitis B Research of Amsterdam
|
N/A |